Compare Crispr Therapeutics AG (CRSP) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Crispr Therapeutics AG trades at $50.3 (market cap $4.97B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.58 (market cap $75.48B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 15.2× Crispr Therapeutics AG's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MDLZ | |
|---|---|---|
Market Cap | $4.97B | $75.48B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $70.75 |
52-Week Low | $44.34 | $51.51 |
Enterprise Value | $3.32B | $95.58B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
MDLZ trades at $59.86, up 1.75% today, with a neutral technical signal and bullish moving averages. Revenue grew to $38.54B in 2025, though net income fell to $2.45B. The company maintains strong brand innovation with recent product launches and a new CFO appointment. Analysts show strong buy sentiment with a $68.00 consensus target, implying 13.6% upside.
Outlook remains positive driven by consistent earnings beats and brand strength, but risks include margin pressure from input costs and competitive headwinds. The stock offers a balanced opportunity for growth investors seeking stable consumer staples exposure with dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
